BioStem Technologies, Inc. (BSEM)
USD 8.3
(1.22%)
USD 8.3
(1.22%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 15.42 Million USD | 157.36% |
| 2022 | 5.99 Million USD | 109.12% |
| 2021 | 2.86 Million USD | 128.94% |
| 2020 | 1.25 Million USD | -4.5% |
| 2019 | 1.31 Million USD | 215.72% |
| 2018 | 415.18 Thousand USD | 132.13% |
| 2017 | 178.85 Thousand USD | -23.17% |
| 2016 | 232.78 Thousand USD | 175.21% |
| 2015 | 84.58 Thousand USD | 171.17% |
| 2014 | 31.19 Thousand USD | 103.76% |
| 2013 | 15.3 Thousand USD | -97.55% |
| 2012 | 624.82 Thousand USD | -40.61% |
| 2011 | 1.05 Million USD | 2.02% |
| 2010 | 1.03 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 39.62 Million USD | 268.92% |
| 2024 Q2 | 70.74 Million USD | 78.39% |
| 2023 FY | 15.19 Million USD | 153.54% |
| 2023 Q2 | 804.03 Thousand USD | 69.29% |
| 2023 Q4 | 10.74 Million USD | 226.3% |
| 2023 Q3 | 3.29 Million USD | 309.41% |
| 2023 Q1 | 474.95 Thousand USD | -28.91% |
| 2022 Q3 | 907.76 Thousand USD | -43.04% |
| 2022 FY | 5.99 Million USD | 109.12% |
| 2022 Q4 | 668.06 Thousand USD | -26.41% |
| 2022 Q1 | 2.5 Million USD | 297.51% |
| 2022 Q2 | 1.59 Million USD | -36.31% |
| 2021 FY | 2.86 Million USD | 128.94% |
| 2021 Q4 | 629.57 Thousand USD | -7.6% |
| 2021 Q1 | 736.09 Thousand USD | 12.15% |
| 2021 Q2 | 413.38 Thousand USD | -43.84% |
| 2021 Q3 | 681.37 Thousand USD | 64.83% |
| 2020 Q1 | 353.78 Thousand USD | -32.54% |
| 2020 Q3 | 210.22 Thousand USD | 568.03% |
| 2020 Q4 | 656.37 Thousand USD | 212.22% |
| 2020 FY | 1.25 Million USD | -4.5% |
| 2020 Q2 | 31.47 Thousand USD | -91.1% |
| 2019 Q1 | 256.4 Thousand USD | 0.0% |
| 2019 FY | 1.31 Million USD | 215.72% |
| 2019 Q4 | 524.45 Thousand USD | 80.91% |
| 2019 Q3 | 289.9 Thousand USD | 20.78% |
| 2019 Q2 | 240.03 Thousand USD | -6.39% |
| 2018 Q1 | 37.81 Thousand USD | 92.75% |
| 2018 FY | 415.18 Thousand USD | 132.13% |
| 2018 Q2 | 15.4 Thousand USD | -59.26% |
| 2017 Q3 | 37.15 Thousand USD | -36.56% |
| 2017 Q4 | 19.62 Thousand USD | -47.19% |
| 2017 FY | 178.85 Thousand USD | -23.17% |
| 2017 Q1 | 66.04 Thousand USD | 53.72% |
| 2017 Q2 | 58.56 Thousand USD | -11.33% |
| 2016 Q1 | 115.26 Thousand USD | 36.27% |
| 2016 Q2 | 130.52 Thousand USD | 13.23% |
| 2016 Q3 | 102.22 Thousand USD | -21.68% |
| 2016 Q4 | 42.96 Thousand USD | -57.97% |
| 2016 FY | 232.78 Thousand USD | 175.21% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q4 | 84.58 Thousand USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | -100.0% |
| 2015 FY | 84.58 Thousand USD | 171.17% |
| 2014 Q4 | 31.19 Thousand USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2014 FY | 31.19 Thousand USD | 103.76% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2013 Q3 | 15.3 Thousand USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | 15.3 Thousand USD | -97.55% |
| 2013 Q4 | - USD | -100.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | 624.82 Thousand USD | -40.61% |
| 2011 FY | 1.05 Million USD | 2.02% |
| 2010 FY | 1.03 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 632525.051% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -31.769% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 4927.702% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 87.05% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 159.791% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 32062.633% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 12514.264% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -2.839% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -497154.9% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -57.493% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -23367.696% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 45267.927% |
| Mesoblast Limited | -35.16 Million USD | 143.86% |
| Marizyme, Inc. | 457.7 Thousand USD | -3270.063% |
| Genus plc | 178.7 Million USD | 91.368% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 92.992% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -24688.428% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -3660.644% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 140325.882% |
| ContraFect Corporation | -154 Thousand USD | 10116.134% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 30949.694% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -19994.641% |
| IMV Inc. | -962.29 Thousand USD | 1702.918% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 4080.595% |
| MultiCell Technologies, Inc. | 49.32 USD | -31274934.469% |
| ONE Bio Corp. | 20.12 Million USD | 23.356% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 61.692% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -31443.654% |
| Q BioMed Inc. | -8988.00 USD | 171716.01% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 45.408% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 100105.491% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 65.226% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 1451.194% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -21935.496% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 311587.217% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -10878.539% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 15917.922% |
| GB Sciences, Inc. | -624.00 USD | 2472030.609% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 18030.031% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.796% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 7415891.827% |
| Enzolytics Inc. | 30.7 Thousand USD | -50130.712% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -3097.303% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 98.608% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 3097.968% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -2398.42% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 96.234% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 174273.972% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 18495.982% |
| Kadimastem Ltd | -630.13 Thousand USD | 2547.852% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -1461.249% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -60.492% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 130432.463% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -8636.32% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -8636.32% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | -1036.568% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 53289.128% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -3327.416% |
| SYBLEU INC | 11.69 Thousand USD | -131781.387% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -234.741% |
| Bioxytran, Inc. | -8285.00 USD | 186277.996% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 4235.348% |
| Neutra Corp. | 14.33 Thousand USD | -107502.7% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 18910.789% |
| PureTech Health plc | -1.6 Million USD | 1062.249% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 1640.581% |
| IXICO plc | 3.27 Million USD | -371.708% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 2322.6% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 961.242% |
| CSL Limited | 7.7 Billion USD | 99.8% |
| Cellectis S.A. | 18 Thousand USD | -85593.594% |